EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieVergleichsstudie

Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer

Rima Patel, Jami Fukui, Paula Klein, Erin Moshier, Hulya Kocyigit, Laura Fiedler, Weronika Bucwinska, Xiao Y Xing, Charles Shapiro, Anupama Goel, Julie Fasano, Theresa Shao und 6 weitere

Breast Cancer Research and Treatment · 2025

DOI: 10.1007/s10549-025-07802-7 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von Rima Patel und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, 1176 Fifth Ave,…. Hauptthemen laut MEDLINE: Everolimus, Triple Negative Breast Neoplasms, Carboplatin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 30 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Triple-negative breast cancers (TNBCs) are associated with a high frequency of PTEN loss, which can lead to activation of the mTOR pathway and tumor proliferation but may be reversible with the mTOR inhibitor everolimus. A prior phase II single-arm trial of carboplatin and everolimus in patients with advanced TNBC demonstrated good tolerability and preliminary efficacy. PATIENTS AND METHODS: A phase II randomized trial in patients with advanced TNBC, with 0-3 prior lines of therapy, was conducted. Patients were randomized 2:1 to receive carboplatin and everolimus or carboplatin alone. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), overall response rate (ORR), clinical benefit rate (CBR), and safety. RESULTS: Between 2015 and 2022, 59 patients were randomized to carboplatin/everolimus (n = 38) or carboplatin alone (n = 21). The median age of the population was 62 years and 68% had received at least one prior line of therapy. Median PFS was significantly improved in patients who received carboplatin/everolimus (4.7 months) versus carboplatin alone (4.2 months; HR:0.49; 95% CI: 0.25-0.98; p = 0.0390). OS was 17.6 months with the combination and 14.6 months with carboplatin alone (HR:1.17; 95% CI: 0.59-2.30; p = 0.6593). The most common adverse events (AEs) on the combination included thrombocytopenia, anemia, leukopenia, and neutropenia. CONCLUSION: The combination of carboplatin and everolimus in this study reduced the risk of progression or death by 52%. The regimen was well tolerated and provides a promising treatment option for patients with advanced TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EverolimusTriple Negative Breast NeoplasmsCarboplatinAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAgedAdultNeoplasm StagingTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

MetastaticTargeted therapyTriple negative breast cancer

Substanzen

EverolimusCarboplatin

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, 1176 Fifth Ave, New York, NY, 10029, USA.
  • University of Hawaii Cancer Center, Honolulu, HI, USA.
  • Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Medicine, Karamanoglu Mehmetbey University, Karaman, Turkey.
  • Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Patel, R., Fukui, J., Klein, P., Moshier, E., Kocyigit, H., Fiedler, L., Bucwinska, W., Xing, X. Y., Shapiro, C., Goel, A., Fasano, J., Shao, T., Bhardwaj, A., Kim, E., Vaccaro, R., Lee, K., Wilck, E., & Tiersten, A. (2025). Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-025-07802-7

Vancouver

Patel R, Fukui J, Klein P, Moshier E, Kocyigit H, Fiedler L, et al. Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-025-07802-7

BibTeX
@article{Patel2025,
  author = {Patel, Rima and Fukui, Jami and Klein, Paula and Moshier, Erin and Kocyigit, Hulya and Fiedler, Laura and Bucwinska, Weronika and Xing, Xiao Y and Shapiro, Charles and Goel, Anupama and Fasano, Julie and Shao, Theresa and Bhardwaj, Aarti and Kim, Esther and Vaccaro, Rita and Lee, Karen and Wilck, Eric and Tiersten, Amy},
  title = {Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer},
  journal = {Breast Cancer Research and Treatment},
  year = {2025},
  doi = {10.1007/s10549-025-07802-7}
}
Kostenlos starten →